Menarini licenses biweekly GLP-1 bofanglutide in Europe in deal worth up to €726m
Menarini has licensed European rights to Gan & Lee’s twice-monthly GLP-1 bofanglutide after a 640-patient Phase 3 study produced up to 18.54% mean weight loss at 52 weeks.